These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16514811)

  • 1. [Allicor efficacy in lowering the risk of ischemic heart disease in primary prophylaxis].
    Sobenin IA; Prianishnikov VV; Kunnova LM; Rabinovich EA; Orekhov AN
    Ter Arkh; 2005; 77(12):9-13. PubMed ID: 16514811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of allicor to lower the risk of myocardial infarction].
    Sobenin IA; Prianishnikov VV; Kunnova LM; Rabinovich EA; Orekhov AN
    Klin Med (Mosk); 2007; 85(3):25-8. PubMed ID: 17523399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypotensive effect of long-acting garlic tablets allicor (a double-blind placebo-controlled trial)].
    Andrianova IV; Fomchenkov IV; Orekhov AN
    Ter Arkh; 2002; 74(3):76-8. PubMed ID: 11980131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reduction of cardiovascular risk in primary prophylaxy of coronary heart disease].
    Sobenin IA; Prianishnikov VV; Kunnova LM; Radinovich EA; Orekhov AN
    Klin Med (Mosk); 2005; 83(4):52-5. PubMed ID: 15941145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correction of hyperlipidemia with Allicor].
    Andrianova IV; Demidova OM; Medvedeva LA; Latyshev OA
    Klin Med (Mosk); 2004; 82(4):56-8. PubMed ID: 15164512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of garlic allicor tablets on lipid metabolism and risk of fatal cardiovascular complications in patients with atherogenic dyslipoproteinemia].
    Gromnatskiĭ NI; Sereditskaia ZhE; Lazareva NV; Sereditskiĭ AV; Annenkova GV
    Vopr Pitan; 2007; 76(6):60-4. PubMed ID: 18219944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus.
    Ashraf R; Aamir K; Shaikh AR; Ahmed T
    J Ayub Med Coll Abbottabad; 2005; 17(3):60-4. PubMed ID: 16320801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of allikor for the normalization of fibrinolysis and hemostasis in patients with chronic cerebrovascular diseases].
    Andrianova IV; Ionova VG; Demina EG; Shabalina AA; Karabasova IaA; Liutova LI; Povorinskaia TE; Orekhov AN
    Klin Med (Mosk); 2001; 79(11):55-8. PubMed ID: 11811113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-released garlic powder tablets lower systolic and diastolic blood pressure in men with mild and moderate arterial hypertension.
    Sobenin IA; Andrianova IV; Fomchenkov IV; Gorchakova TV; Orekhov AN
    Hypertens Res; 2009 Jun; 32(6):433-7. PubMed ID: 19390538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study.
    Sobenin IA; Nedosugova LV; Filatova LV; Balabolkin MI; Gorchakova TV; Orekhov AN
    Acta Diabetol; 2008 Mar; 45(1):1-6. PubMed ID: 17823766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Primary prevention of ischemic heart disease in middle-aged men living in Prague: results of twenty-year research].
    Boudík F; Reissigová J; Hrach K; Tomecková M; Bultas J; Anger Z; Aschermann M; Zvárová J
    Vnitr Lek; 2006 Apr; 52(4):339-47. PubMed ID: 16755990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of long-acting garlic tablets "allicor" on the incidence of acute respiratory viral infections in children].
    Andrianova IV; Sobenin IA; Sereda EV; Borodina LI; Studenikin MI
    Ter Arkh; 2003; 75(3):53-6. PubMed ID: 12718222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevalence of ischemic heart disease, basic risk factors, and efficacy of long-term multifactorial prophylaxis at work in some regions of Russia].
    Tozhiev MS; Norbekov MS; Shestov DB; Khvan IuE; Vorob'ev AM; Terebov AA; Suiundikov ShT; Marchenko AM; Kashirina ML; Klimova MIu
    Ter Arkh; 2004; 76(1):33-8. PubMed ID: 15108435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
    Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
    J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis.
    Ishii H; Toriyama T; Aoyama T; Takahashi H; Yamada S; Kasuga H; Ichimiya S; Kanashiro M; Mitsuhashi H; Maruyama S; Matsuo S; Naruse K; Matsubara T; Murohara T
    Clin Ther; 2007 Jan; 29(1):110-22. PubMed ID: 17379051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
    Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
    Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study.
    Benn M; Nordestgaard BG; Jensen GB; Tybjaerg-Hansen A
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):661-70. PubMed ID: 17170368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics.
    Ong HT; Cheah JS
    Chin Med J (Engl); 2008 Aug; 121(16):1588-94. PubMed ID: 18982874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.